2024-510840-30-00招募中2 期
EORTC-1532-GUCG: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer.
European Organisation For Research And Treatment Of Cancer12 个研究点 分布在 4 个国家目标入组 169 人开始时间: 2024年5月23日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 169
- 试验地点
- 12
- 主要终点
- The primary endpoint is the PSA response assessed at 24 weeks. PSA response is defined as a ≥ 80% decline in PSA measurement taken at week 24 relative to the measurement taken at baseline, in the darolutamide study arm. The ADT arm is used as an internal control.
研究概览
简要总结
The primary trial objective is to demonstrate that darolutamide produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥ 80% reduction compared to baseline) that are in the range of those achieved with 24 weeks of ADT.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older
- •Able to swallow the study drug whole as a tablet
- •Adequate bone marrow function • absolute neutrophil count (ANC) ≥ 1.5 109/L. • hemoglobin ≥ 10.0 g/dl. • platelets ≥ 100 109/L.
- •Adequate renal function: creatinine ≤ 1.5 x ULN
- •Albumin > 25 g/L
- •Adequate hepatic function: • Bilirubin: total bilirubin ≤ 1.5 × upper limit of normal (ULN). • AST and/or ALT ≤ 2.5 × ULN.
- •Normal 12-lead ECG as per local standard
- •Patients of reproductive potential should use adequate birth control measures, during the study treatment period and for at least 3 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
- •Histologically confirmed prostate cancer (all stages) for whom continuous ADT is indicated for a minimum period of 24 weeks
- •M0 patients or those presenting with a maximum of 4 confirmed metastatic lesions, including bone, extra-pelvic lymph nodes, and > 2 cm pelvic lymph nodes by imaging (contrast enhanced CT scans or MRI, Tc-99m BS according to local practice, see section 6.1.1). Visceral metastases are excluded
- •Asymptomatic for metastatic prostate cancer; urinary symptoms are allowed
- •Baseline total testosterone ≥ 8 nmol/L or 230 ng/dL
- •Two subsequent PSA values ≥ 2 ng/ml, done in the past 3 months (prior to enrollment) with a minimum of 2 weeks between the two, with the second being equal to or higher than the first
- •WHO performance status (PS) of 0-1
- •G8 score ≥ 14 for patients aged ≥ 70 years old
- •A life expectancy of at least 12 months
排除标准
- •Previously or currently receiving hormonal therapy with intent to treat prostate cancer disease (surgical castration or other hormonal manipulation, e.g. LHRH agonists, LHRH antagonists, anti-androgens, oestrogens, 5α-reductase inhibitor). For patients that have received (neo)adjuvant ADT before radiotherapy, it should have been stopped for more than 1 year
- •History of prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer from which the patient has been disease-free for a period of at least 5 years.
- •Clinically significant cardiovascular disease including: • Myocardial infarction within 6 months prior to randomization • Uncontrolled angina within 3 months prior to randomization • Coronary/peripheral artery bypass within 6 months prior to randomization • Stroke within 6 months prior to randomization • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months results in a left ventricular ejection fraction that is ≥ 45% • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes) • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
- •Uncontrolled hypertension as indicated by a resting systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at the screening visit
- •Prior use of investigational agents that block androgen synthesis or block androgen receptor
- •Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g. saw palmetto)
- •Has received systemic glucocorticoids within 24 weeks prior to enrollment or is expected to require systemic glucocorticoids during the study period, unless determined to be medically necessary by the investigator for other indications than prostate cancer
- •Radiation therapy for treatment of the primary tumor within 3 months prior to enrollment
- •Use of an investigational agent within 4 weeks prior to enrollment is not allowed
- •Gastrointestinal disorder affecting absorption (e.g. gastrectomy, active peptic ulcer disease) within 3 months prior to enrollment
- •Known hypersensitivity to the study treatment or any of its ingredients (refer to Investigator's brochure).
- •Severe or uncontrolled concurrent disease, infection or co-morbidity including active viral hepatitis, known human immunodeficiency virus infection with detectable viral load (HIV) or chronic liver disease (Child Pugh C)
结局指标
主要结局
The primary endpoint is the PSA response assessed at 24 weeks. PSA response is defined as a ≥ 80% decline in PSA measurement taken at week 24 relative to the measurement taken at baseline, in the darolutamide study arm. The ADT arm is used as an internal control.
The primary endpoint is the PSA response assessed at 24 weeks. PSA response is defined as a ≥ 80% decline in PSA measurement taken at week 24 relative to the measurement taken at baseline, in the darolutamide study arm. The ADT arm is used as an internal control.
次要结局
- The main key secondary endpoint in this study is the change in hormone-treatment related symptoms scale of the EORTC QLQ-PR25 at 24 weeks compared to baseline in the darolutamide study arm. A 10-point difference is regarded as a clinically meaningful benefit.
- Safety according to NCI-CTC version 4.0
- Objective response rate at 24 weeks in patients with RECIST 1.1 measurable disease at baseline
- PSA complete response rate at 24 weeks defined as a ≥ 90% decline in PSA measurement at week 24 relative to the measurement taken at baseline
研究者
Stéphanie Kromar
Scientific
European Organisation For Research And Treatment Of Cancer
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
A phase 2 Randomized Open-Label Study of Oral ODM-201 vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate CancerHormone Naive Prostate CancerMedDRA version: 20.0Level: PTClassification code 10071119Term: Hormone-dependent prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004334-17-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)250
进行中（未招募）
1 期
A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate CancerHormone Naive Prostate CancerMedDRA version: 21.1Level: PTClassification code 10071119Term: Hormone-dependent prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004334-17-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)250
进行中（未招募）
1 期
A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate CancerHormone Naive Prostate CancerMedDRA version: 21.1Level: PTClassification code 10071119Term: Hormone-dependent prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004334-17-ATEuropean Organisation for Research and Treatment of Cancer (EORTC)250
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination of cyclophosphamide and dexamethasone improves the response to therapy in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatmentewly diagnosed multiple myelomaMedDRA version: 14.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2013-003113-17-GRMillennium Pharmaceuticals, Inc.70
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination of cyclophosphamide and dexamethasone improves the response to therapy in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment, and in patients with multiple myeloma whose disease is no longer responding or has not responded to previous treatmentEUCTR2013-003113-17-SEMillennium Pharmaceuticals, Inc.148